Jiangsu Hengrui Medicine Co., Ltd. Jiangsu Hengrui Medicine Co., Ltd.

Jiangsu Hengrui Medicine Co., Ltd.

600276

Kedudukan dalam Saham #544
Jiangsu Hengrui Medicine Co., Ltd. is a global biopharmaceutical firm engaged... Jiangsu Hengrui Medicine Co., Ltd. is a global biopharmaceutical firm engaged in the full spectrum of pharmaceutical operations, from the initial discovery and development of medications to their manufacturing and worldwide distribution. The company is actively advancing a substantial pipeline of drug candidates, which includes Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403. These prospective treatments are aimed at a diverse range of medical conditions, primarily focusing on oncology, metabolic disorders, pain management, and autoimmune diseases, among others. The enterprise was founded in 1970 and maintains its corporate headquarters in Lianyungang, China.
Harga Saham
$6.89
Modal Pasaran
$43.94B
Perubahan (1 hari)
-2.91%
Perubahan (1 tahun)
-24.78%
Negara
CN
Perdagangan Jiangsu Hengrui Medicine Co., Ltd. (600276)

Kategori

Healthcare
Nisbah P/B bagi Jiangsu Hengrui Medicine Co., Ltd. (600276)
Nisbah P/B pada October 2026 TTM: 4.71
Menurut laporan kewangan dan harga saham terkini Jiangsu Hengrui Medicine Co., Ltd., nisbah P/B semasa (TTM) ialah 4.71. Pada akhir 2024, nisbah P/B syarikat ialah 6.39.
Sejarah nisbah P/B untuk Jiangsu Hengrui Medicine Co., Ltd. dari 2001 hingga 2026
Nisbah P/B pada akhir setiap tahun
Tahun Nisbah P/B Ubah
2026 (TTM) 4.71 -25.48%
2025 6.32 -1.09%
2024 6.39 -9.65%
2023 7.07 9.04%
2022 6.49 -29.84%
2021 9.24 -52.24%
2020 19.35 24.50%
2019 15.55 57.24%
2018 9.89 -5.23%
2017 10.43 45.32%
2016 7.18 -10.85%
2015 8.05 63.76%
2014 4.92 -13.09%
2013 5.66 13.80%
2012 4.97 -8.81%
2011 5.45 -40.25%
2010 9.12 4.84%
2009 8.70 25.59%
2008 6.93 -35.14%
2007 10.68 89.97%
2006 5.62 451.70%
2005 1.02 5.76%
2004 0.96 -9.87%
2003 1.07 -10.67%
2002 1.20 -6.19%
2001 1.28 0.00%
Nisbah P/B untuk syarikat atau pesaing yang serupa